Micro-costing study of rituximab subcutaneous injection versus intravenous infusion in dutch setting

J. Mihajlović, P. Bax, E. Van Breugel, H.M. Blommestein, M. Hoogendoorn, W. Hospes, M.J. Postma

Research output: Contribution to journalMeeting AbstractAcademic

648 Downloads (Pure)


Background: Rituximab for subcutaneous (SC) administration has recently been approved for use in common forms of diffuse large B-cell lymphoma (DLBCL). This form of rituximab is supplied in ready-to-use vials that do not require individual dose adjustment. It is expected that SC-injection will shorten the treatment time per administration of rituximab in comparison with currently available intravenous (IV) infusion. Aims: The goal of this study is to identify and compare all direct costs of IV and SC rituximab given to the DLBCL patients in the Netherlands. Methods: Using a prospective, observational, bottom up, micro-costing study we collected primary data on the direct medical costs of the preparation, administration and acquisition of rituximab. Drug costs and spillage, labor costs, material costs and remaining daycare costs were identified using standardized forms, structured using guideline prices and compared for the IV and SC forms of rituximab. Results: Measurements were done on 53 administrations (33 IV and 20 SC). The mean total costs of the IV infusion were €2174, and €1907 for the SC injection. The estimated difference of €267 per administration was mainly due to spillage costs and differences in chair time, related daycare costs and drug costs. Summary and Conclusions: Rituximab administered in the form of SC injection is less costly than its IV form. Taking into account their equal effectiveness, favorable pharmacoeconomic profile of SC rituximab can result in significant savings when transferred to the total DLBCL population in the Netherlands.
Original languageEnglish
Pages (from-to)582
Number of pages1
Publication statusPublished - 22-Jun-2015
Event20th Congress of the European Hematology Association Vienna, Austria, June 11–14, 2015 - Vienna, Austria
Duration: 11-Jun-201514-Jun-2015


  • rituximab
  • subcutaneous drug administration
  • intravenous drug administration
  • European
  • hematology
  • injection
  • Netherlands
  • day care
  • spillage
  • drug cost
  • large cell lymphoma
  • patient
  • human
  • population

Cite this